These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18251162)

  • 1. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma.
    Hotta N; Ayada M; Sato K; Ishikawa T; Okumura A; Matsumoto E; Ohashi T; Kakumu S
    Hepatogastroenterology; 2007; 54(79):2073-7. PubMed ID: 18251162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study.
    Mizuta T; Ozaki I; Eguchi Y; Yasutake T; Kawazoe S; Fujimoto K; Yamamoto K
    Cancer; 2006 Feb; 106(4):867-72. PubMed ID: 16400650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection.
    Kakizaki S; Sohara N; Sato K; Suzuki H; Yanagisawa M; Nakajima H; Takagi H; Naganuma A; Otsuka T; Takahashi H; Hamada T; Mori M
    J Gastroenterol Hepatol; 2007 Apr; 22(4):518-22. PubMed ID: 17376044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.
    Yoshida H; Shiratori Y; Kudo M; Shiina S; Mizuta T; Kojiro M; Yamamoto K; Koike Y; Saito K; Koyanagi N; Kawabe T; Kawazoe S; Kobashi H; Kasugai H; Osaki Y; Araki Y; Izumi N; Oka H; Tsuji K; Toyota J; Seki T; Osawa T; Masaki N; Ichinose M; Seike M; Ishikawa A; Ueno Y; Tagawa K; Kuromatsu R; Sakisaka S; Ikeda H; Kuroda H; Kokuryu H; Yamashita T; Sakaida I; Katamoto T; Kikuchi K; Nomoto M; Omata M
    Hepatology; 2011 Aug; 54(2):532-40. PubMed ID: 21574174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma.
    Peng B; Liang L; Chen Z; He Q; Kuang M; Zhou F; Lu M; Huang J
    Hepatogastroenterology; 2006; 53(69):409-14. PubMed ID: 16795983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
    Yoshiji H; Noguchi R; Toyohara M; Ikenaka Y; Kitade M; Kaji K; Yamazaki M; Yamao J; Mitoro A; Sawai M; Yoshida M; Fujimoto M; Tsujimoto T; Kawaratani H; Uemura M; Fukui H
    J Hepatol; 2009 Aug; 51(2):315-21. PubMed ID: 19501932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy.
    Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Kinoshita H
    Br J Surg; 2002 Apr; 89(4):418-22. PubMed ID: 11952580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma.
    Okuwaki Y; Nakazawa T; Kokubu S; Hidaka H; Tanaka Y; Takada J; Watanabe M; Shibuya A; Minamino T; Saigenji K
    Am J Gastroenterol; 2009 Nov; 104(11):2747-53. PubMed ID: 19603009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma and vitamin K.
    Mizuta T; Ozaki I
    Vitam Horm; 2008; 78():435-42. PubMed ID: 18374204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma].
    Zhou QM; Wu PH; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 Nov; 25(11):1414-8. PubMed ID: 17094912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma--results of 152 resected cases.
    Shirabe K; Wakiyama S; Gion T; Motomura K; Koyanagi T; Sakamoto S; Nagaie T
    Hepatogastroenterology; 2007; 54(79):2084-7. PubMed ID: 18251164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors.
    Yin XY; Xie XY; Lu MD; Xu HX; Xu ZF; Kuang M; Liu GJ; Liang JY; Lau WY
    Cancer; 2009 May; 115(9):1914-23. PubMed ID: 19241423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.
    Lin SM; Lin CJ; Hsu CW; Tai DI; Sheen IS; Lin DY; Liaw YF
    Cancer; 2004 Jan; 100(2):376-82. PubMed ID: 14716774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial.
    Ishizuka M; Kubota K; Shimoda M; Kita J; Kato M; Park KH; Shiraki T
    Anticancer Res; 2012 Dec; 32(12):5415-20. PubMed ID: 23225445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of early hepatocellular carcinoma after hepatic resection.
    Maeda T; Shimada M; Harimoto N; Tsujita E; Aishima S; Tanaka S; Shirabe K; Maehara Y
    Hepatogastroenterology; 2008; 55(85):1428-32. PubMed ID: 18795705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas.
    Ohmoto K; Yoshioka N; Tomiyama Y; Shibata N; Kawase T; Yoshida K; Kuboki M; Yamamoto S
    J Gastroenterol Hepatol; 2009 Feb; 24(2):223-7. PubMed ID: 18823439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
    Zou WL; Zang YJ; Chen XG; Shen ZY
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma.
    Katz SC; Shia J; Liau KH; Gonen M; Ruo L; Jarnagin WR; Fong Y; D'Angelica MI; Blumgart LH; Dematteo RP
    Ann Surg; 2009 Apr; 249(4):617-23. PubMed ID: 19300227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma.
    Lam VW; Ng KK; Chok KS; Cheung TT; Yuen J; Tung H; Tso WK; Fan ST; Poon RT
    J Am Coll Surg; 2008 Jul; 207(1):20-9. PubMed ID: 18589357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study.
    Kawano Y; Sasaki A; Kai S; Endo Y; Iwaki K; Uchida H; Shibata K; Ohta M; Kitano S
    Eur J Surg Oncol; 2009 Feb; 35(2):174-9. PubMed ID: 18325724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.